Morgan Stanley maintains Hims and Hers stock rating at equalweight

Published 04/06/2025, 11:08
Morgan Stanley maintains Hims and Hers stock rating at equalweight

On Wednesday, Morgan Stanley (NYSE:MS) analysts maintained their Equalweight rating on Hims and Hers stock (NYSE:HIMS) with a price target of $40, placing it within the broader analyst range of $25-$85. Trading at $54.73, the stock currently appears overvalued according to InvestingPro analysis. This decision follows the company’s announcement of its acquisition of Zava, a strategic move that aligns with its recent $1 billion convertible senior notes offering and the hiring of COO Nader Kabbani, who brings international operational experience.

Hims and Hers aims to complete the Zava acquisition in the second half of 2025, with expectations for it to contribute positively to earnings by 2026. The company’s management had previously indicated plans for international expansion in its Q1 shareholder letter and through its recent convertible offering.

The acquisition of Zava is part of Hims and Hers’ broader strategy to enhance its growth profile. While detailed information about the acquisition remains limited, discussions are ongoing about its potential impact on the company’s gross margin mix and vertical integration opportunities.

Hims and Hers’ management has set ambitious targets for 2030, aiming for $6.5 billion in revenue and $1.3 billion in EBITDA. The recent acquisition is seen as a step toward achieving these goals, although analysts note that the current stock technicals may be outpacing the company’s fundamentals.

In other recent news, Hims and Hers announced its acquisition of ZAVA, a European telehealth provider, marking a strategic move to expand its presence internationally. The company plans to extend its services to countries like the UK, Germany, France, and Ireland, aiming to offer personalized care in various health sectors. The acquisition is anticipated to become accretive by 2026, with completion expected in the second half of 2025. Analysts from TD Cowen and Truist Securities maintained a Hold rating on Hims and Hers, with price targets of $38.00 and $45.00, respectively, while Citi maintained a Sell rating with a $30.00 target. Leerink Partners reiterated a Market Perform rating with a $42.00 target, noting potential integration challenges. Meanwhile, BofA Securities analysts maintained an Underperform rating with a $28.00 target, citing concerns about order growth slowdown and international expansion risks. Despite differing opinions, analysts agree that the acquisition aligns with Hims and Hers’ strategy to broaden its geographic reach. The company raised substantial debt to support this expansion, and analysts are keenly observing how these developments will impact Hims and Hers’ financial performance and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.